Technology
Most Popular Under $25
Health

Zynerba Pharmaceuticals

$13.80
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.35 (-2.59%) Today
+$0.62 (4.70%) After Hours

Why Robinhood?

You can buy or sell ZYNE and other stocks, options, ETFs, and crypto commission-free!

About

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It engages in the development and commercialization of transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neurological and psychiatric, or neuropsychiatric, disorders in patients with high unmet medical needs. Read More The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

Employees
25
Headquarters
Devon, Pennsylvania
Founded
2007
Market Cap
277.77M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.03M
High Today
$14.40
Low Today
$13.05
Open Price
$13.75
Volume
753.10K
52 Week High
$16.47
52 Week Low
$2.75

Collections

Technology
Most Popular Under $25
Health
Pharmaceutical
Medical
2015 IPO
US
North America

News

Yahoo FinanceMay 8

Is Zynerba Pharmaceuticals (ZYNE) Outperforming Other Medical Stocks This Year?

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -1.03% and -1.94%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock? Investors focused on the Medical space have likely heard of Zynerba Pharmaceuticals (ZYNE), but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out. Zynerba Pharmaceuticals is one of 844 individual stock...

7,538
Yahoo FinanceMay 8

Zynerba Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights

DEVON, Pa., May 08, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the first quarter ended March 31, 2019 and provided an overview of recent operational highlights. “We are entering a transformational period for Zynerba during which we expect top line data from four neuropsychiatric disorder trials with Zygel™, our paten...

5,531
NasdaqMay 6

Why Zynerba Pharmaceuticals Stock Zoomed Higher Today

What happened Shares of Zynerba Pharmaceuticals (NASDAQ: ZYNE) were zooming 10.7% higher as of 3:13 p.m. EDT on Monday. The biotech announced earlier in the day that the Food and Drug Administration granted Fast Track Designation to cannibidiol (CBD) gel Zygel for the treatment of behavioral symptoms associated with Fragile X syndrome (FXS). So what Zynerba has enjoyed its fair share of good news lately. The biotech's share price also jumped last week after Roth Capital initiated coverage on the stock wi...

2,826

Earnings

-$0.91
-$0.75
-$0.60
-$0.44
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.